<DOC>
	<DOCNO>NCT02223611</DOCNO>
	<brief_summary>The purpose study evaluate S1 capsule plus Cisplatin adjuvant treatment stageⅡ Ⅲa non-small cell lung cancer . It first study world investigate safety efficacy S1 capsule use stageⅡ Ⅲa non-small cell lung cancer patient complete resection .</brief_summary>
	<brief_title>Clinical Observation S1 Capsule Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection</brief_title>
	<detailed_description>Lung cancer lead cause cancer death worldwide . Only 15.6 % lung cancer patient alive 5years diagnosis . Non-small Cell Lung Cancer ( NSCLC ) account 85 % lung cancer case . For individual stage Ⅱ-ⅢA NSCLC complete resection , platinum-based chemotherapy mainstay first line treatment . Various treatment regimen develop improve survival . S-1 capsule novel oral anticancer drug combine tegafur , prodrug 5-fluorouracil , gimeracil oteracil potassium . S-1 capsule consider active single agent NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patient completely resect stage ⅢA nonsmall cell lung cancer ( NSCLC ) Must able receive therapy study within four week completely resection Systemic anticancer treatment local radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Stage Ⅱ-ⅢA NSCLC S1 capsule Completely resection</keyword>
</DOC>